HR 7640 · 117th Congress · Health

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

Introduced 2022-05-03· Sponsored by Rep. Bilirakis, Gus M. [R-FL-12]· House

Bill Progress

✓
Introduced
2
Committee
3
House Vote
4
Senate
5
Enacted
Latest: Referred to the House Committee on Energy and Commerce.(2022-05-03)

Plain Language Summary

[AI summary unavailable — showing source text] This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.…

Summarized by Claude AI · Non-partisan · For informational purposes only

Cosponsors (1)

1 Democrat
Rep. Butterfield, G. K. [D-NC-1]NC